paroxetine has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrews, AM; Murphy, DL | 1 |
| Chung, YC; Jin, BK; Kim, SR | 1 |
2 other study(ies) available for paroxetine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
2'-NH2-MPTP in Swiss Webster mice: evidence for long-term (6-month) depletions in cortical and hippocampal serotonin and norepinephrine, differential protection by selective uptake inhibitors or clorgyline and functional changes in central serotonin neuro
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cerebral Cortex; Clorgyline; Desipramine; Fluoxetine; Hippocampus; Male; Mice; Monoamine Oxidase Inhibitors; MPTP Poisoning; Neurotransmitter Uptake Inhibitors; Norepinephrine; Paroxetine; Selegiline; Serotonin; Serotonin Receptor Agonists; Synaptic Transmission; Time Factors | 1993 |
Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antidepressive Agents, Second-Generation; Blotting, Western; Brain; Dopamine; Enzyme Activation; Immunohistochemistry; Inflammation; Interleukin-1beta; Male; Mice; Mice, Inbred C57BL; Motor Activity; NADPH Oxidases; Neurons; Nitric Oxide Synthase Type II; Oxidative Stress; Parkinson Disease, Secondary; Paroxetine; Peroxidase; Reverse Transcriptase Polymerase Chain Reaction; Substantia Nigra; Tumor Necrosis Factor-alpha | 2010 |